These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35863718)

  • 1. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
    Chen Y; Tso K; Heckrodt TJ; Li H; Yen R; Lin N; Singh R; Taylor V; Masuda ES; Park G; Payan DG
    Bioorg Med Chem Lett; 2022 Oct; 73():128900. PubMed ID: 35863718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.
    Chen Y; Singh R; Lin N; Taylor V; Masuda ES; Payan DG
    ACS Med Chem Lett; 2022 Apr; 13(4):714-719. PubMed ID: 35450353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
    Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
    McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
    Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
    Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
    J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
    Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
    J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity.
    Kim TW; Staschke K; Bulek K; Yao J; Peters K; Oh KH; Vandenburg Y; Xiao H; Qian W; Hamilton T; Min B; Sen G; Gilmour R; Li X
    J Exp Med; 2007 May; 204(5):1025-36. PubMed ID: 17470642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.
    Cushing L; Stochaj W; Siegel M; Czerwinski R; Dower K; Wright Q; Hirschfield M; Casanova JL; Picard C; Puel A; Lin LL; Rao VR
    J Biol Chem; 2014 Apr; 289(15):10865-10875. PubMed ID: 24567333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
    Hao Y; Ma J; Wang J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
    Eur J Med Chem; 2023 Oct; 258():115616. PubMed ID: 37413880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.
    De S; Karim F; Kiessu E; Cushing L; Lin LL; Ghandil P; Hoarau C; Casanova JL; Puel A; Rao VR
    J Biol Chem; 2018 Sep; 293(39):15208-15220. PubMed ID: 30115681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
    Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Fischmann T; Gibeau C; Kleinschek MA; Leccese E; Lesburg C; Maclean JK; Moy LY; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Steinhuebel D; Yang R
    ACS Med Chem Lett; 2015 Jun; 6(6):683-8. PubMed ID: 26101574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
    McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
    Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
    J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications.
    Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Kleinschek MA; Li C; Liu D; Maclean JK; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Yang R
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5384-8. PubMed ID: 26403930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
    Seganish WM
    Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
    McElroy WT
    Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.
    Staschke KA; Dong S; Saha J; Zhao J; Brooks NA; Hepburn DL; Xia J; Gulen MF; Kang Z; Altuntas CZ; Tuohy VK; Gilmour R; Li X; Na S
    J Immunol; 2009 Jul; 183(1):568-77. PubMed ID: 19542468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of IRAK4 inhibitor activity prediction model based on machine learning.
    Zhao Y; Wan Q; He X
    Mol Divers; 2024 Aug; 28(4):2289-2300. PubMed ID: 38970641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.